Redox Signaling to Nuclear Regulatory Proteins by Reactive Oxygen Species Contributes to Estrogen-Induced Growth of Breast Cancer Cells
Investigators demonstrated of oxidative modification of phosphatases PTEN and CDC25A by 17β-Estradiol (E2)-generated reactive oxygen species (ROS) along with the subsequent activation of AKT and ERK pathways that culminated in the activation of nuclear respiratory factor-1 leading to the upregulation of cell cycle genes. E2-induced ROS by influencing nuclear proteins p27 and Jab1 also contributed to the growth of MCF-7 cells. [Br J Cancer]
Abstract
CD44 Expression Contributes to Trastuzumab Resistance in HER2-Positive Breast Cancer Cells
Researchers hypothesized that CD44 contributes to trastuzumab resistance independently of its role as a cancer stem cell marker. They used trastuzumab-sensitive breast cancer cell lines and their trastuzumab-resistant isogenic counterparts to evaluate the role of CD44 in response to trastuzumab. [Breast Cancer Res Treat] Abstract
Circulating Tumor Cell Clusters-Associated Gene Plakoglobin and Breast Cancer Survival
The authors summarize the studies on the roles of plakoglobin and evaluate the association of plakoglobin and breast cancer survival. Plakoglobin may be a potential prognostic biomarker that can be exploited to develop as a therapeutic target for breast cancer. [Breast Cancer Res Treat] Abstract
Visit our reviews page to see a complete list of reviews in the mammary cell research field.
SCIENCE NEWS
Generex Provides Data Update from AE37 Phase II Breast Cancer Trial One Year Post Completion of Enrollment
Generex Biotechnology Corporation announced that updated data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine under development at the company’s wholly-owned subsidiary, Antigen Express, Inc. will be presented. [Press release from Generex Biotechnology Corporation discussing research to be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago]
Press Release
Propanc to Study Effects of PRP on Cancer Stem Cells
Propanc Health Group Corporation announced that the company will be investigating the effects of PRP against cancer stems cells with its joint research partner at the University of Jaén, Spain. [Propanc Health Group Corporation] Press Release
Redx Reaches Pre-Clinical Proof of Concept with Oncology Lead
Redx Pharma has reached pre-clinical proof of concept stage with an advanced lead which has the potential to tackle some of the most hard-to-treat cancers. The novel, potent small molecule Porcupine inhibitor targets the Wnt pathway, an embryonic signaling pathway that is implicated in the maintenance of cancer stem cells in multiple cancer types. [Redx Pharma Plc] Press Release
Yang Receives AACR Career Development Award
Shih-Hsin Yang, M.D., Ph.D., associate professor at the University of Alabama at Birmingham, has been awarded the 2015 American Association for Cancer Research (AACR)-Triple Negative Breast Cancer Foundation Career Development Award for clinical/translational research. [University of Alabama at Birmingham] Press Release
Recruit Top Talent:
Reach more than 60,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Mammary Cell News? Click here to submit!
